L
Laura Giordano
Researcher at Humanitas University
Publications - 130
Citations - 2772
Laura Giordano is an academic researcher from Humanitas University. The author has contributed to research in topics: Transplantation & Cancer. The author has an hindex of 27, co-authored 115 publications receiving 2287 citations.
Papers
More filters
Journal ArticleDOI
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
Nicola Personeni,Silvia Bozzarelli,Tiziana Pressiani,Lorenza Rimassa,Maria Chiara Tronconi,Francesco Sclafani,Carlo Carnaghi,Vittorio Pedicini,Laura Giordano,Armando Santoro +9 more
TL;DR: Assessment of AFP response may be considered as an alternative to RECIST to capture sorafenib activity in HCC and improve prognostic usefulness of imaging-based Response Evaluation Criteria in Solid Tumors.
Journal ArticleDOI
Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.
Barbara Sarina,Luca Castagna,Lucia Farina,Francesca Patriarca,Fabio Benedetti,Angelo Michele Carella,Michele Falda,Stefano Guidi,Fabio Ciceri,Alessandro Bonini,Samantha Ferrari,Michele Malagola,Enrico Morello,Giuseppe Milone,Benedetto Bruno,Nicola Mordini,Simonetta Viviani,Alessandro Levis,Laura Giordano,Armando Santoro,Paolo Corradini +20 more
TL;DR: This is the largest study comparing RIC alloSCT versus conventional treatment after a failed autoSCT, indicating a survival benefit for patients having a donor and patients allografted in complete remission showed a better PFS and OS.
Journal ArticleDOI
Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma
A M Raiola,Alida Dominietto,Riccardo Varaldo,A. Ghiso,Federica Galaverna,S Bramanti,Elisabetta Todisco,Barbara Sarina,Laura Giordano,Adalberto Ibatici,Antonella Santoro,Marino Clavio,Almalina Bacigalupo,Luca Castagna +13 more
TL;DR: It is confirmed that high-dose PT-CY is effective as prophylaxis of GVHD after HLA haploidentical BMT, can prevent rejection and does not appear to eliminate the allogeneic graft versus lymphoma effect.
Journal ArticleDOI
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T. Pressiani,Corrado Boni,Lorenza Rimassa,R. Labianca,Stefano Fagiuoli,Stefania Salvagni,Daris Ferrari,Enrico Cortesi,Camillo Porta,Claudia Mucciarini,L. Latini,C. Carnaghi,Maria Banzi,Silvia Fanello,M. De Giorgio,Fabio Romano Lutman,Guido Torzilli,M. A. Tommasini,R. Ceriani,Giovanni Covini,Maria Chiara Tronconi,Laura Giordano,N. Locopo,S. Naimo,Armando Santoro +24 more
TL;DR: Data suggest that patients with CP class B liver function can tolerate treatment and may still benefit from sorafenib, although patients with HCC and CP class A liver function have poorer outcomes than those withCP class A function.
Journal ArticleDOI
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
Giovanni Luca Ceresoli,Paolo Andrea Zucali,Fabio De Vincenzo,Letizia Gianoncelli,Matteo Simonelli,Elena Lorenzi,C. Ripa,Laura Giordano,Armando Santoro +8 more
TL;DR: Re-treatment with PBC should be considered as second-line therapy in MPM patients achieving a durable (>12 months) disease control with first-line PBC.